Peer-reviewed veterinary case report
New blood test markers found for heart disease in dogs
By Ro, Woong-Bin et al.·Published in Frontiers in veterinary science·2021·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Identification and Characterization of Circulating MicroRNAs as Novel Biomarkers in Dogs With Heart Diseases.
- Species:
- dog
Plain-English summary
A study found that certain microRNAs (small molecules in the blood) could help identify dogs with heart diseases. Researchers looked at blood samples from 82 dogs, including 72 with heart issues and 10 healthy ones. They discovered that a specific microRNA, cfa-miR-130b, was higher in dogs with myxomatous mitral valve degeneration (a common heart condition) and could help distinguish sick dogs from healthy ones. Other microRNAs, cfa-miR-375 and cfa-let-7b, were linked to a different heart problem called concentric cardiac hypertrophy. These findings suggest that these microRNAs could be useful for diagnosing and potentially treating heart diseases in dogs.
People also search for: dog heart disease symptoms · microRNA biomarkers in dogs · treatment for dog heart problems · myxomatous mitral valve degeneration in dogs
Abstract
Previous studies in humans have confirmed dysregulations of circulating microRNAs (miRNAs) in patients with various cardiovascular diseases. However, studies on circulating miRNAs in dogs with various heart diseases are limited in number. This study aimed to identify significantly dysregulated circulating miRNAs and characterize them as novel biomarkers in dogs with heart diseases.Circulating levels of 11 miRNAs were investigated in serum samples of 82 dogs (72 with heart diseases and 10 healthy dogs) using quantitative reverse transcription-polymerase chain reaction. The results were correlated to clinical data including echocardiographic results and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels.Upregulation of cfa-miR-130b was observed in dogs with myxomatous mitral valve degeneration (MMVD) stage B, patent ductus arteriosus, and pulmonic stenosis. In dogs with MMVD stage B, cfa-miR-130b was upregulated and correlated with clinical indices. In receiver operating characteristic (ROC) analysis, cfa-miR-130b accurately distinguished dogs with diseases from healthy dogs. We also observed that cfa-miR-375 and cfa-let-7b were upregulated in dogs with concentric cardiac hypertrophy. The cfa-miR-375 was correlated with concentric hypertrophy indices and was an accurate indicator of concentric hypertrophy in ROC analysis.The miRNAs identified in this study may be used as novel biomarkers and possible candidates for therapeutic targets in various canine heart diseases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34708100/